This study investigated the prognostic value of immune-related adverse events, spleen-to-liver ratio, and bone marrow-to-liver ratio detected by or measured on [18F]FDG-PET/CT in a population of patients with resected high-risk melanoma, treated with adjuvant anti-PD-1. Here, PDCD1 is linked to melanoma.